Introduction
============

The modern molecular diagnostic field is faced with the problem of an increasing spectrum of analysis from decreasing amounts of tissue, providing the opportunity for "tailored" therapy beneficial for the patient. The current approaches focus on collecting more material for the preferred molecular analysis, eg, by using cryobiopsies for evaluation of lymph node tissue in lung cancer.[@b1-ott-7-1441]--[@b3-ott-7-1441] With respect to the patients health, a better way would be to improve the preamplification methods already in use to accumulate an adequate amount of DNA/RNA for all types of analysis required. Although many different types of preamplification methods have been published and evaluated, none of them have been accepted for routine diagnostics.[@b4-ott-7-1441]--[@b17-ott-7-1441]

In our opinion, a promising and powerful DNA preamplification method for this application is isothermal multiple displacement amplification (IMDA). This is an isothermal preamplification method that combines the advantages of non-thermostable DNA polymerases with a high yield reaction.[@b10-ott-7-1441],[@b11-ott-7-1441],[@b14-ott-7-1441],[@b18-ott-7-1441]--[@b21-ott-7-1441] Whole-genome amplification methods (WGA) using thermostable DNA polymerases may often generate non-specific amplification artifacts, resulting in an incomplete coverage of loci and/or generating very short DNA fragments.[@b18-ott-7-1441] Compared with other whole-genome amplification methods, IMDA, reported for the first time by Dean et al in 2002,[@b18-ott-7-1441] shows a highly uniform coverage across the genome and generates high molecular weight genomic DNA (up to \>70 kb in length). This method is already validated for clinical specimens[@b10-ott-7-1441],[@b11-ott-7-1441] as well as for formalin-fixed paraffin-embedded (FFPE) tissue.[@b5-ott-7-1441],[@b10-ott-7-1441] In microbiology, IMDA has become state of the art as a prepolymerase chain reaction (PCR) method to amplify difficult samples and low copy number sequences.[@b22-ott-7-1441] It is sufficient to start with an input of only a few laser-capture microdissected cells for whole-genome amplification to generate an adequate amount of DNA for further molecular analysis.

The aim of this study was to confirm the convenience and feasibility of IMDA for routine molecular diagnostics using very small tumor samples, including small biopsies with a low number of malignant cells or microcarcinomas.

Materials and methods
=====================

Study design
------------

To confirm the feasibility of IMDA for routine molecular pathological diagnostics, different FFPE lung tissue samples were microdissected and subsequently preamplified by IMDA. For pretesting of amplification efficiency, only benign tissue was used. To test the homogeneity of the amplification at different chromosomal loci, 33 targets distributed all over the human genome (at least one on every chromosome) were tested by SYBR-green (Life Technologies, Carlsbad, CA, USA) quantitative PCR analysis. Afterwards, human lung adenocarcinoma samples were resequenced after initial DNA preamplification using IMDA for known *EGFR* exon 21 c.2573T\>G (p.L858R) point mutations by Sanger sequencing. Well known activating *EGFR* exon 19 deletions were determined using agarose gel electrophoresis. The known *EGFR* exon 19 deletions can be clearly separated by this method. In addition, the same tumor samples were sequenced by pyrosequencing for possible *ERCC1* exon 4 c.19007T\>C (p.N118N) and 3′-UTR c.8092C\>A polymorphisms, respectively.

Samples and patients
--------------------

Only FFPE tissue was used. FFPE preparation was performed according to the institutional standards. The fresh tissue was fixed in 4% buffered formalin for 24 hours, then diced to approximately 0.5 × 1.0 × 1.0 cm dimensions and embedded in paraffin. For diagnostic classification, one to four, \<1 μm thick sections were used for immunohistochemistry and staining with hematoxylin and eosin.

For evaluation of IMDA, ten benign lung tissue samples were selected for pretesting. Additionally, for sequence analysis, four lung cancer specimens were selected for evaluation. One sample contained a known deletion in exon 19 of the *EGFR* gene and another sample contained a known p.L858R point mutation in exon 21 of the *EGFR* gene. The remaining two tumor samples included in the analysis show a wild-type *EGFR* gene locus. Cells for subsequent IMDA were separated from inflammation and leukocytes by microdissection.

Microdissection
---------------

Sample slides were microdissected using laser-capture microdissection technology (PALM RoboMover; Zeiss, Jena, Germany). Zeiss MembraneSlide NF 1.0 PEN glass slides were used due to the plastic film affixed on the slides. The Robo-LPC computer program was used to assist the microdissection procedure.

For tissue lysis prior to IMDA amplification, Qiagen FFPE lysis solution (Qiagen, Hilden, Germany), which is applied in the REPLI-g FFPE kit (Qiagen), was used; 20 μL was directly dropped into the cap of the microdissection tube. The microdissected tumor areas had dimensions in the range of 50 × 50 μm to 150 × 100 μm correlating with an average of approximately 25 tumor cell nuclei.

IMDA preamplification
---------------------

The commercial REPLI-g FFPE kit (Qiagen) was used for IMDA. This assay combines a ligase reaction to generate high molecular weight DNA templates from degraded FFPE tissue with IMDA DNA preamplification. Genomic DNA from the lysed tissue was denatured at room temperature for 3 minutes and then incubated with random primers. Strand displacement synthesis was performed at 30°C according to the manufacturer's recommendations. As the amplification reaction reaches a plateau after approximately 8 hours, the reaction was terminated by incubation at 60°C for 10 minutes.

DNA quantification was done using a Qubit dsDNA BR assay kit (Invitrogen, Carlsbad, CA, USA).

Amplification products were stored at 4°C until further use.

Analysis of chromosomal coverage
--------------------------------

To test for the presence of all chromosomes/target sequences in the amplified DNA, randomly chosen genes spanning regions on every chromosome were quantitatively tested using Platinum SYBR Green quantitative PCR SuperMix-UDG (Invitrogen). In addition, on four chromosomes, multiple gene loci were amplified to test the relative representation of different regions on these chromosomes. Quantitative analysis was performed on a 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA, USA). The 2\^-ΔCt method was used to normalize target Ct's versus reference Ct's. To ensure amplification of the probably highly degraded genomic DNA from the FFPE tissue, amplicons for quantitative PCR reaction were designed with a maximum length of 100 bp. All primer sequences are listed in [Table 1](#t1-ott-7-1441){ref-type="table"}, and the PCR protocol is shown in [Table 2](#t2-ott-7-1441){ref-type="table"}.

Mutational analysis
-------------------

Sanger sequencing was performed on an Applied Biosystems 3500 genetic analyzer according to the manufacturer's protocol (BigDye Terminator v3.1 cycle sequencing kit; Applied Biosystems) with a halved reaction volume. Pyrosequencing was performed on a PyroMark Q24 (Qiagen). For data analysis, the Qiagen PyroMark Q24 software was used. Sequencing was done according to the Qiagen PyroMark Q24 protocol. Streptavidin sepharose (GE Healthcare, Chalfont, UK) was used instead of streptavidin-coated beads. Sequences of all sequencing primers are listed in [Table 3](#t3-ott-7-1441){ref-type="table"}.

Results
=======

IMDA preamplification
---------------------

IMDA was successful in all (malignant and benign) samples. With an input of approximately 20--25 cells (equaling approximately 175 pg of genomic DNA) for laser-capture microdissection, 3 μg/μL up to more than 5 μg/μL DNA was generated with a reaction volume of 50 μL. The actual amount of suitable DNA amplified strongly depends on the duration of the final amplification step.

The best results were obtained with an amplification duration of 8 hours. At this point, all quantitative PCR analyses showed sufficient results; nevertheless the amplification efficiency showed small disparities. The age of the tissue slides, did not show an influence on the qualtity of the quantitative PCR template. All negative controls showed no results.

Chromosomal coverage
--------------------

All tested genes on all chromosomes could be detected. However, the detected gene loci differed in their amplification ([Figure 1](#f1-ott-7-1441){ref-type="fig"}). Both the chi-squared test and Fisher's Exact test showed a significant independency for amplification (*P* equals nearly 1). Also, within the chromosomes, there were clear differences ([Figure 1](#f1-ott-7-1441){ref-type="fig"}). Differences in amplification efficiency between the analyzed gene loci ranged up to 3.8-fold between the median 2\^-ΔCt values of each locus.

The amplified sequence seems not to have a major impact on this phenomenon; it rather depends on the quality of DNA in the tissue slides being investigated than on the parameters of the target sequence. Most of the amplified DNA fragments were of a small size. This effect becomes increased by the ligation step, which links together several fragments of distinct genes/regions. Small-sized DNA fragments like these "patchwork fragments" would still be long enough for next-generation sequencing, and the merging of different gene sequences is not problematic, but also for normal "qualitative" analysis, like mutational analysis, the amount of useful amplified DNA is adequate.

Mutational analysis
-------------------

After an initial IMDA preamplification, two specimens were tested for known *EGFR* mutations (exon 19 deletions and exon 21 p.L858R point mutations) by capillary sequencing. Both mutations could be detected reproducibly in all replications ([Figure 2](#f2-ott-7-1441){ref-type="fig"}). In two patient samples that contained the *EGFR* wild-type sequence and served as negative controls, no mutations could be detected after IMDA preamplification.

The same four specimens were used for pyrosequencing of *ERCC1* point mutations at the c.19007T\>C and c.8092C\>A mutation hotspot of *ERCC1.* Sequencing was successful in all four cases. One case showed an *ERCC1* exon 4 c.19007T\>C, whereas the others were classified as wild-type ([Figure 3](#f3-ott-7-1441){ref-type="fig"}). For *ERCC1* c.8092C\>A mutation status, all cases showed a wild-type genotype in comparison with a mutated positive control.

Discussion
==========

The aim of our study was to check the feasibility and convenience of IMDA as an isothermal preamplification method for molecular diagnostics involving notably small sample material.

Our results show outstanding amplification efficiency (250 μg of genomic DNA for approximately 25 cells) and that IMDA is a valuable preamplification method for all further molecular analysis of these clinical specimens. In contrast, recent studies show a five- to ten-fold lower efficiency of IMDA, but these deviances may be based on differences between the quantification methods used.[@b18-ott-7-1441] The additional preceding ligation step to generate DNA templates of higher genomic weight could also be a possible explanation for this phenomenon.

All 33 investigated genes could be amplified and detected by subsequent analysis, although the amplification efficiency was heterogeneous between the tested gene loci, ranging up to 3.8-fold between each locus.

Although a reaction time of 3 hours generated a feasible amount of DNA, the average fragment size seemed to be too short for efficient use as a template for further PCR reactions, even with an amplicon size ranging from 100 bp to 200 bp. In contrast with that, published data for subsequent whole-genome sequencing suggests that this relatively small amplicon size may be sufficient.[@b8-ott-7-1441],[@b10-ott-7-1441],[@b14-ott-7-1441],[@b22-ott-7-1441] The published range bias generated with whole-genome amplification methods lies between six-fold and eight-fold.[@b8-ott-7-1441],[@b10-ott-7-1441],[@b14-ott-7-1441],[@b18-ott-7-1441],[@b22-ott-7-1441] In comparison with that, the methodical bias of IMDA, even for FFPE tissue, is, significantly below.[@b5-ott-7-1441],[@b10-ott-7-1441]

The relatively high bias in our experiment can be explained by the thickness of the tissue slides (1--4 μm); during microdissection, nucleoli may be fragmented, leading to a loss of genetic loci in individual cells. Moreover, all diagnostically relevant genes and mutations were detected after IMDA preamplification. Subsequent sequencing gave evaluable results using two independent sequencing methods (capillary sequencing and pyrosequencing).

New challenges in the upcoming years will require new molecular biological techniques that are currently not established in routine pathology laboratories. Therefore, isothermal amplification methods, originally derived from microbiological work-up processes,[@b12-ott-7-1441],[@b22-ott-7-1441]--[@b24-ott-7-1441] are merely examples of the potential new techniques for modern pathology that can be derived from other fields of research. In this context, the outstanding role of isothermal amplification methods has to be mentioned. Additionally, it is of note that non-thermostable DNA polymerases avoid artificial variants because of their proofreading ability and simultaneously enable the advantages of non-thermostable DNA polymerases.[@b4-ott-7-1441],[@b6-ott-7-1441],[@b11-ott-7-1441],[@b13-ott-7-1441],[@b15-ott-7-1441]--[@b19-ott-7-1441],[@b21-ott-7-1441] Nevertheless, IMDA is not suitable for rapid on-site evaluation during the biopsy process because of the long reaction time. Molecular diagnostics is an evolving field in routine pathology. Therefore, the development and integration of feasible, sensitive, robust and efficient techniques like IMDA is mandatory.

Conclusion
==========

With a reaction time of 8 hours, a feasible amount of amplicons with adequate size for qualitative PCR can be generated using IMDA, starting with input material equaling 25 human cells. Further, tissue slides can be stained with hematoxylin and eosin for microdissection, making it much easier for the pathologist/technical assistant to find tumor cells. Additionally, this method also works with macrodissected (microscope and scalpel) tissue of a surface extension less than 1 mm^3^. For larger tissue samples, routine amplification without IMDA remains the first choice, due to the relatively high costs and additional processing time of IMDA. However, it needs to be borne in mind that every additional processing step promotes more or less bias. Nevertheless, IMDA has proven to be a feasible and robust molecular pathological method to preamplify hitherto hardly analyzable clinical specimens.
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![Amplification strength of tested genes normalized to *GAPDH* and displayed by 2\^-deltaCt values. Six genes show an extraordinary deviation (*VIM*, *FOXO1*, *HBA1*, *AR*, *MAPK1*, *TSPY1*), but most of them have a lower amplification rate (except *TSPY1*). The variances can be explained by the difference in amplification product length and the quality of the template before ligation.\
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###### 

List of all primer sequences used for amplification for relative chromosomal representation analysis

  Gene name   Chromosome   Forward                Reverse
  ----------- ------------ ---------------------- ----------------------
  *MTOR*      1            AAGAGTTCCCGTTCATGTGG   CAGGTGGTAGCTCTGGCTTC
  *CASP8*     2            TCAGAGACCTGCACTTGTGG   AACAACCCAGCAAAGGTGTC
  *AGTR1*     3            ACCTGCTCCTGGTAGAGCAA   CAGCCACACTCTGAGGTGAA
  *VEGFR2*    4            CCGAGTGGGCACAGTTTATT   ACAATTCACACTGCCATCCA
  *IL-4*      5            CAGTTGGAGGGAGTGAGAGC   TGCACAGAGTCTTGGTCCAG
  *IL-13*     5            TGCACGTGCTTTATGTGTCA   GCTTGAATCCAGCCTCTGTC
  *HLA-A*     6            ATTACATCGCCCTGAACGAG   CCAGGTAGGCTCTCAACTGC
  *EGFR*      7            GTACTCACTGTCGCCCCATT   TTCCAAGACGCTTCTGACCT
  *FGFR1*     8            GAACAGGCATGCAAGTGAGA   GCTGTAGCCCTGAGGACAAG
  *CTSB*      8            TCTCGGTCTCAGCCAGTTCT   CCAGTAGGGTGTGCCATTCT
  *ANGPT2*    8            TCATTTGACGCATGACCCTA   GCTCCAAGATCCGTTCTGAG
  *JAK2*      9            CTGCCTTGTGACTGACTGGA   AGCCTACCTGGGCTATCCAT
  *VIM*       10           GGCCCAGCTGTAAGTTGGTA   CCTAGCGGTTTAGGGGAAAC
  *HBB*       11           TTGGACCCAGAGGTTCTTTG   CACTAAAGGCACCGAGCACT
  *GAPDH*     12           CGACCACTTTGTCAAGCTCA   AGAGTTGTCAGGGCCCTTTT
  *ERCC5*     13           AGCCCAGTAGCAGGAAGTGA   GAAAACCCTCCAAAGCTTCC
  *FOXO1*     13           CACTGTATGCTCTGGCAGGA   GCAGTCAGGGCTGAGAAATC
  *ERS2*      14           CTACCAGCAGCCCAGCTATC   GTCTTTATGGCCACCCTGAA
  *CYP1A2*    15           TAATCCCCAGCTCTGGTGTC   CATTTTATGCCCCATTGACC
  *HBA1*      16           CCACTGACCCTCTTCTCTGC   GAAGCCAGGAACTTGTCCAG
  *p53*       17           TGTCATCTCTCCTCCCTGCT   TCTGAGTCAGGCCCTTCTGT
  *BCL2*      18           GCTTATCGTCTGCGTGTGAA   GGGATGTGCTCGGTAAGTGT
  *TYMS*      18           TCTGGAAGGGTGTTTTGGAG   AGGATCTCACTGGCTGCTGT
  *ERCC1*     19           AAGGCACTGTCCATTCATCC   TTGAGCTAGGGAGGGTAGCA
  *TOP1*      20           TTGGCTGTTGCAGATAGTGC   CACAGAAATGCCACATGACC
  *ERG*       21           TTCCCTGGGTCTGAAAGATG   ATTGTGTTCTGCGGGTTAGG
  *MAPK1*     22           CTCAGCCTTACCCTTTGCTG   TGTGGTGTGAGGGGTACAGA
  *AR*        X            GGCTGACATACATGGGCTTT   CTGCAATGACCTCACGCTTA
  *TSPY1*     Y            TCGGGGAAGTGTAAGTGACC   CAATAGTACCCACGCCTGCT

**Note:** All generated amplicons are about 100 bp in length.

###### 

Details regarding the PCR conditions

  Reagent mix              Thermocycling program   Cycles                   
  ------------------------ ----------------------- -------- ---- ---------- ----
  PCR buffer (10×)         5.0                     1        95   00:10:00   1
  MgCl~2~                  5.0                     2        95   00:00:30   40
  Primer forward (10 μM)   1.0                              55   00:00:30   
  Primer reverse (10 μM)   1.0                              72   00:01:00   
  dNTPs                    1.0                     3        8    ∞          1
  TaqPol                   0.5                                              
  H~2~O                    35.5                                             
  Template                 1.0                                              
  Total                    50.0                                             

**Notes:** The protocol was used for all performed PCR reactions including quantitative PCR for chromosomal coverage determination as well as PCR for subsequent sequencing procedures. Time in the thermocycling program is expressed in hours, minutes, and seconds.

**Abbreviations:** dNTPs, deoxynucleotide triphosphates; PCR, polymerase chain reaction; hh, hours; mm, minutes; ss, seconds.

###### 

List of primers used for pyrosequencing and amplification

  Method              Gene name           Direction                                    Sequence
  ------------------- ------------------- -------------------------------------------- ------------------------------------------
  Sanger sequencing   *EGFR* exon 19      Forward                                      TATGTAAAACGACGGCCAGTTGGCACCATCTCACAATTGC
  *EGFR* exon 19      Reverse             TATTATAGGGCGAATTGGGTGCTGCCAGACATGAGAAAAGG    
  *EGFR* exon 21      Forward             TATGTAAAACGACGGCCAGTAACTACTTGGAGGACCGTCGC    
  *EGFR* exon 21      Reverse             TATTATAGGGCGAATTGGGTTCCTTACTTTGCCTCCTTCTGC   
  *EGFR* exon 21      Sequencing (F)      GTAAAACGACGGCCAGT                            
  *EGFR* exon 21      Sequencing (R)      TATAGGGCGAATTGGGT                            
  Pyrosequencing      *ERCC1* codon 118   Forward                                      **BIO**-TCCCTATTGATGGCTTCTGC
  *ERCC1* codon 118   Reverse             TCCAGAACACTGGGACATGA                         
  *ERCC1* codon 118   Sequencing          ACGTCGCCAAATTCCCAGGG                         
  *ERCC1* C8092A      Forward             TGAGCCAATTCAGCCACT                           
  *ERCC1* C8092A      Reverse             **BIO**-TAGTTCCTCAGTTTCCCG                   
  *ERCC1* C8092A      Sequencing          AGGCCGGGACAAGAAGCGGA                         

**Note:** One of the amplification primers always has a biotin (**BIO**) tag for purification and linkage to the streptavidin-coated beads.

**Abbreviations:** Sequencing (F), forward primer used for sequencing; Sequencing (R), reverse primer used for sequencing.
